UBS AM’s Terns Pharmaceuticals TERN Stock Holding History

UBS AM’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-94,646	Closed	-$4.99M	–	3862
2026 Q1	$4.99M	Buy	94,646 +94,028	+15,215%	+$3.86M	﹤0.01%	1557
2025 Q4	$25K	Buy	+618	New	+$14.3K	﹤0.01%	2707
2024 Q2	–	Sell	-17,870	Closed	-$117K	–	2878
2024 Q1	$117K	Hold	17,870	–	–	﹤0.01%	2491
2023 Q4	$116K	Buy	+17,870	New	+$94.5K	﹤0.01%	2522

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS AM's TERN Position: Q2 2026 in Review

UBS AM sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 94,646 shares — an estimated $4.99M sold.

UBS AM first reported a position in TERN in Q4 2023 and held it in 4 quarters. The position peaked at $4.99M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

UBS AM reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
UBS AM sold 94,646 Terns Pharmaceuticals shares in Q2 2026, an estimated $4.99M.
UBS AM first reported a position in Terns Pharmaceuticals in Q4 2023 and held it in 4 quarters.
UBS AM's Terns Pharmaceuticals position peaked at $4.99M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.